INVO Fertility Enters into $7.5 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
INVO Fertility (NASDAQ: IVF) entered a warrant inducement agreement to lower the exercise price of December 2025 warrants to $1.59 and has an investor agreeing to immediately exercise warrants to buy 4,733,728 shares, generating approximately $7.5 million gross proceeds before fees.
The company will issue 9,467,456 new unregistered warrants at $1.59 per share, subject to shareholder approval, and expects to close the exercise on or about January 30, 2026, subject to customary conditions.
Positive
- Expected gross proceeds of approximately $7.5 million
- Immediate conversion of 4,733,728 warrants into common stock
- Commitment to file a SEC registration for resale of new-warrant shares
Negative
- Issuance of 9,467,456 new warrants creates substantial potential dilution
- New warrants are unregistered and offered privately pending shareholder approval
- Shareholder approval requirement may delay exercise or issuance timetable
News Market Reaction – IVF
In the Jan 29 session, IVF declined 12.96%, reflecting a significant negative market reaction. Argus tracked a trough of -18.4% from its starting point during tracking. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Conference participation | Neutral | -4.8% | Announcement of participation in Lytham Partners 2026 investor healthcare summit. |
| Dec 30 | Leadership realignment | Positive | +10.0% | Executive structure realigned to support clinic acquisition growth strategy. |
| Dec 17 | Clinic acquisition deal | Positive | -9.8% | Definitive agreement to acquire Family Beginnings fertility clinic non-clinical assets. |
| Dec 02 | Private placement financing | Negative | -11.8% | At-the-market private placement with warrants for gross proceeds of $4.0M. |
| Nov 28 | Acquisition intent | Positive | +11.0% | Intent announced to acquire Family Beginnings fertility clinic in Indianapolis. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent capital-raising news (Dec 2 private placement) coincided with double-digit share price declines, while acquisition and strategy news have produced mixed but often strong reactions in both directions.
Over the past few months, IVF has combined financing actions with a clinic acquisition strategy. A Dec 2, 2025 private placement with warrants for $4.0M coincided with a -11.83% move. Announcements about acquiring the Family Beginnings clinic, first as an intent on Nov 28 and then via definitive agreement on Dec 17, saw strong but opposite reactions of +10.96% and -9.75%. Leadership realignment on Dec 30 aligned with a +9.99% move, while a conference participation update on Jan 13 preceded a -4.82% decline.
Key Terms
warrant inducement agreement financial
at-the-market financial
nasdaq rules regulatory
unregistered warrants financial
registration statement regulatory
securities and exchange commission regulatory
private placement financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SARASOTA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on December 3, 2025 (the “December 2025 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to a reduced exercise price of the outstanding December 2025 Warrants to an amended exercise price of
Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction.
In consideration for the immediate exercise of the existing warrants, the Company also agreed to issue to the investor unregistered warrants to purchase an aggregate of 9,467,456 shares of the Company’s common stock with an exercise price of
The closing of the warrant exercise transactions is expected to occur on or about January 30, 2026, subject to satisfaction of customary closing conditions.
The New Warrants described above are being offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit www.invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding the Company’s ability to satisfy closing conditions for the offering, our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com
Investor Contact:
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
